China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Common Equity for 9 consecutive years, with $29.7 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 92.41% year-over-year to $29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (up 92.41% YoY) and the FY2026 annual result came in at $29.7 million, up 92.41% from the prior year.
• Common Equity rose to $29.7 million in Q1 2026 per SXTC's latest filing, from $20.2 million in the prior quarter.
• Over the last five years, Common Equity for SXTC reached as high as $29.7 million in Q1 2026 and fell as low as $5.1 million in Q3 2023.
• A 5-year average of $16.1 million and a median of $15.0 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity sank 65.11% — and 2024, when it surged 196.18%.
• Year by year, Common Equity stood at $14.5 million in 2022, then plunged by 65.11% to $5.1 million in 2023, then jumped by 196.18% to $15.0 million in 2024, then jumped by 34.58% to $20.2 million in 2025, then soared by 46.82% to $29.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $29.7 million, $20.2 million, and $15.4 million for Q1 2026, Q3 2025, and Q1 2025 respectively.